Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by β-lactam-susceptible and highly resistant pneumococci. by Rodríguez-Cerrato, Violeta et al.
Accepted Manuscript
Title: Comparative efficacy of novobiocin and amoxicillin in
experimental sepsis caused by -lactam-susceptible and
highly resistant pneumococci
Authors: Violeta Rodrı´guez-Cerrato, Gema del Prado, Lorena
Huelves, Plı´nio Naves, Vicente Ruiz, Ernesto Garcı´a, Carmen
Ponte, Francisco Soriano
PII: S0924-8579(10)00081-6
DOI: doi:10.1016/j.ijantimicag.2010.02.007
Reference: ANTAGE 3257
To appear in: International Journal of Antimicrobial Agents
Received date: 30-11-2009
Revised date: 1-2-2010
Accepted date: 10-2-2010
Please cite this article as: Rodrı´guez-Cerrato V, del Prado G, Huelves L, Naves
P, Ruiz V, Garcı´a E, Ponte C, Soriano F, Comparative efficacy of novobiocin
and amoxicillin in experimental sepsis caused by -lactam-susceptible and highly
resistant pneumococci, International Journal of Antimicrobial Agents (2008),
doi:10.1016/j.ijantimicag.2010.02.007
This is a PDF file of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its final form. Please note that during the production process
errors may be discovered which could affect the content, and all legal disclaimers that
apply to the journal pertain.
Page 1 of 27
Ac
ce
pte
d M
an
us
cri
pt
 1 
Comparative efficacy of novobiocin and amoxicillin in 
experimental sepsis caused by -lactam-susceptible and highly 
resistant pneumococci 
 
Violeta Rodríguez-Cerrato a,*, Gema del Prado b, Lorena Huelves b, Plínio 
Naves b, Vicente Ruiz b, Ernesto García a, Carmen Ponte b, Francisco Soriano b 
 
a Department of Molecular Microbiology and Infection Biology, Centro de 
Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain 
b Department of Medical Microbiology and Antimicrobial Chemotherapy, 
Fundación Jiménez Díaz–Capio, Avenida de Reyes Católicos 2, 28040 Madrid, 
Spain 
 
ARTICLE INFO 
Article history: 
Received 30 November 2009 
Accepted 10 February 2010 
 
Keywords: 
Streptococcus pneumoniae 
Antibiotic resistance 
Sepsis 
Novobiocin  
 
* Corresponding author. Tel.: +34 918 373 112 x4417; fax: +34 915 360 432. 
Edited manuscript
Page 2 of 27
Ac
ce
pte
d M
an
us
cri
pt
 2 
E-mail address: vrodriguez@cib.csic.es (V. Rodríguez-Cerrato). 
Page 3 of 27
Ac
ce
pte
d M
an
us
cri
pt
 3 
ABSTRACT 
Therapeutic alternatives are needed against infections caused by highly 
multidrug-resistant Streptococcus pneumoniae. Novobiocin, an old antibiotic, 
was tested in vitro and in a murine sepsis model against one amoxicillin-
susceptible and three amoxicillin-resistant strains [minimum inhibitory 
concentrations (MICs) 8–64 mg/L]. Novobiocin MICs for all strains were 0.25–
0.5 mg/L. In sepsis, novobiocin and amoxicillin were evaluated at 25, 50, 100 
and 200 mg/kg given at 1, 5, 24 and 48 h post bacterial challenge. The most 
effective regimens in animals infected with the amoxicillin-susceptible strain 
were 200 mg/kg novobiocin and 25 mg/kg amoxicillin, achieving 100% survival 
and undetectable organisms in the peritoneum. Among mice infected with 
amoxicillin-resistant S. pneumoniae, 200 mg/kg novobiocin gave the highest 
protection (90–100% survivors), followed by 200 mg/kg amoxicillin (60–100%), 
100 mg/kg novobiocin (50–87.5%) and 50 mg/kg amoxicillin (14.3–25%). The 
killing effect of antibiotics in the peritoneum (mean log10 colony-forming 
units/mL between treated and control mice) was as follows: 200 mg/kg 
novobiocin (6.6) > 200 mg/kg amoxicillin (5.6) > 100 mg/kg novobiocin (3.7) 
> 50 mg/kg amoxicillin (0.7). Total plasma and ultrafiltrate pharmacokinetics of 
novobiocin (200 mg/kg, single dose) in non-infected mice showed, respectively, 
half-lives of 151 min and 215 min, area under the concentration–time curves 
(AUCs) of 945.0 mg h/L and 136.6 mg h/L and maximal concentrations of 147 
mg/L and 18 mg/L. Novobiocin may be a promising agent for therapy of highly 
-lactam-resistant pneumococcal infections. 
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1. Introduction 
The emergence and steady spread of antibiotic-resistant bacterial pathogens 
are global public health concerns. In particular, the rapid rise of antibiotic 
resistance among Streptococcus pneumoniae has complicated the therapy of 
pneumococcal infections both in adults and children [1–4]. Therapeutic 
strategies for combating antibiotic-resistant pneumococcal infections are 
currently being explored, including the possibility of reviving old active drugs. 
Based on previous reports showing remarkable in vitro activity of novobiocin 
against S. pneumoniae [5,6], we have re-evaluated in vitro and in vivo the 
antipneumococcal activity of this out-of-the-market antibiotic, which was 
licensed until recently as an antibiotic for human use in many countries such as 
the USA and in Europe (i.e. Albamycin® 200 mg capsules for oral 
administration; Pharmacia-Upjohn). 
 
Novobiocin, an aminocoumarin natural product elaborated by streptomycetes, 
was widely used as an antibacterial agent in the 1950s and 1960s. Novobiocin 
is an inhibitor of bacterial DNA gyrase. Like other coumarin products, it binds 
more tightly to gyrase (as reflected by equilibrium dissociation constants in the 
range of 10 nM [7]) than do typical quinolones, and novobiocin also causes 
inhibition of ATP binding [8]. Novobiocin was used for the treatment of a variety 
of infections caused by susceptible organisms, including pneumococcal 
pneumonia [9]. However, several reports published in the 1950s regarding the 
emergence of resistance and side effects [10–12], along with the development 
of other antibiotics (i.e. penicillinase-resistant penicillins), likely determined the 
lack of usage of this otherwise potent and inexpensive antibiotic. 
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The aims of this study were to investigate the in vitro activity, pharmacokinetics 
and effectiveness of novobiocin therapy using a murine sepsis model caused by 
amoxicillin-susceptible and -resistant S. pneumoniae strains. 
 
2. Material and methods 
2.1. Bacterial strains and antibiotics 
Four clinical strains of S. pneumoniae were used in this study, for which the 
serotype, origin and penicillin minimum inhibitory concentration (MIC) were as 
follows: strain AR33118, serotype 3, blood, MIC = 0.015 mg/L; strain MJD3693, 
19F, cerebrospinal fluid, MIC = 2 mg/L; strain SPC2162, 19A, blood, MIC = 16 
mg/L; and strain SPC2552, 23F, respiratory tract, MIC = 32 mg/L). Novobiocin 
sodium salt (N6160; Sigma-Aldrich Chemie GmbH, Steinheim, Germany) was 
used for in vitro and in vivo studies. Amoxicillin trihydrate of known potency 
(GlaxoSmithKline S.A., Madrid, Spain) and amoxicillin sodium salt (Clamoxyl® 1 
g; GlaxoSmithKline S.A.) were used for in vitro and in vivo studies, respectively. 
 
2.2. Minimum inhibitory concentrations and time–kill analysis 
MICs of novobiocin and amoxicillin for the various strains were determined by 
the microdilution method approved by the Clinical and Laboratory Standards 
Institute (CLSI) [13] using cation-adjusted Mueller–Hinton II broth (Becton, 
Dickinson and Co., Le Pont-de-Claix, France) supplemented with 4% lysed 
horse blood (CA-MHB-LHB). Modal values of three separate determinations 
were considered. 
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Time–kill assays were performed by exposing cultures of the various strains to 
novobiocin or amoxicillin at 2, 8 or 32 MIC, except for the strain that was 
most resistant to penicillin (strain SPC2552) for which the amoxicillin 
concentration of 32 MIC was not tested owing to poor solubility of the powder. 
Bacteria were grown in broth to early log phase and then inoculated tubes with 
CA-MHB-LHB were incubated at 35 C in normal atmosphere at a final titre of 2 
 106 colony-forming units (CFU)/mL. Samples of 100 L were removed at the 
time of inoculation (time zero) and after 2 h and 5 h, diluted and plated on blood 
agar plates for colony counting. The killing effects of antibiotics were thus 
compared by determining the change in log10 CFU/mL at 2 h and 5 h compared 
with counts in the control tubes at each time point, and such differences in 
bacterial titres were expressed as negative values. Antibiotic carryover was 
minimised by dilution. Each test was performed in duplicate. 
 
2.3. Mouse sepsis model 
Experimental animals were adult female Swiss mice weighing 30  2 g (Centro 
de Investigaciones Biológicas, Madrid, Spain). Animals were housed in 
regulation cages with free access to food and water. 
 
For animal inoculation, pneumococcal suspensions were prepared immediately 
before use by suspending colonies from fresh overnight cultures on 5% blood 
agar plates in sterile Todd–Hewitt broth (THB), adjusted to an optical density 
giving a concentration of ca. 5  108 CFU/mL. For the penicillin-susceptible 
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strain, the suspension was further diluted into THB to a final inoculum ranging 
from 4.8  102 to 1.3  104 CFU/mL. For the three penicillin-resistant strains and 
immediately before inoculation, the bacterial suspensions were diluted 1:10 in 
molten nutrient agar, which was used as adjuvant for inoculation of the mice, 
yielding a final agar concentration of 1.5% (w/v) and a final inoculum ranging 
from 4.2  107 to 1.4  108 CFU/mL. Sepsis with each strain was induced by 
intraperitoneal (i.p.) injection of 0.5 mL of inoculum into non-anaesthetised mice 
1 h before therapy with antibiotics or apyrogen sterile distilled water (control). 
These inocula were 80–100% lethal within 1–3 days and provided a consistently 
high number of bacteria in the peritoneal cavity. The inoculum size was 
confirmed by determination of the bacterial titre in each experiment. The 
potential lethal effect of agar alone was examined by i.p. injection of 0.5 mL of 
1.5% (w/v) agar–THB solution to three animals. None of these animals 
appeared ill or died within the 72 h period of observation. 
 
2.4. Treatment protocols 
Treatment of mice was performed as a subcutaneous (s.c.) injection in a 
volume of 0.1 mL per dose in the neck region. For the efficacy studies, four 
doses of antibiotics were given at 1, 5, 24 and 48 h after infection, and survival 
was recorded daily throughout the study period, which ended 72 h after 
inoculation. At the end of the study, animals were euthanised by CO2 overdose, 
and peritoneal lavage fluid specimens were collected and processed for CFU 
determination. Peritoneal lavage was also performed post-mortem in animals 
that were found dead before finishing the experiment. The results of peritoneal 
bacterial load were expressed as mean ± standard deviation (S.D.) log10 
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CFU/mL. Differences in the number of CFU/mL between treated and control 
animals were calculated to compare the effectiveness of the treatment 
regimens. The lower limit of organism quantification in these studies was 10 
CFU/mL. 
 
Two types of experiments were performed to evaluate the effectiveness of 
antibiotic therapy, and the most effective antimicrobial regimen was defined as 
the regimen that achieved the highest survival rate and the most potent 
antibacterial effect in the peritoneal fluid. 
 
2.4.1. Drug effectiveness in sepsis caused by a penicillin-susceptible strain 
Mice with sepsis induced by the penicillin-susceptible strain (AR33118) received 
novobiocin (25, 50, 100 or 200 mg/kg) or amoxicillin (25 mg/kg). A group of 
mice received apyrogen sterile distilled water as control for the lethality and the 
peritoneal bacterial load of the infection. Mostly, five to seven mice were used 
for each regimen in these dose-ranging experiments. 
 
2.4.2. Drug effectiveness in sepsis caused by penicillin-resistant strains 
Following infection with each of the three penicillin-resistant S. pneumoniae 
strains, mice were treated with doses of novobiocin at 100 mg/kg or 200 mg/kg 
or amoxicillin at 50 mg/kg or 200 mg/kg. A group of mice that received apyrogen 
sterile distilled water was tested as control. Each regimen was given to mice in 
groups of at least seven animals (range, seven to ten animals). Survival was 
noted daily and peritoneal bacterial loads were determined as above. 
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2.5. Pharmacokinetics and tolerance of novobiocin 
A single-dose plasma pharmacokinetic (PK) study of novobiocin was performed 
in non-infected mice given s.c. doses of novobiocin at 200 mg/kg. For each time 
point, three mice were sampled by cardiac puncture (immediately after 
euthanasia with CO2 overdose) at 15, 30, 60, 120, 240, 360, 540 and 720 min 
after injection with heparin-rinsed syringes. Blood samples were centrifuged at 
5000  g for 10 min. The plasma obtained was divided into two parts and one of 
them was centrifuged in tubes with filters with a cut-off of ca. 30 kDa 
(Centrifree® YM-30; Millipore, Carrigtwohill, Ireland) in a fixed-angle rotor at 
3000  g for 12 min. Both samples were stored at 20 C until analysis. 
 
Novobiocin concentrations were determined by an agar diffusion microbiological 
assay using Kocuria rhizophila (previously designated as Micrococcus luteus) 
ATCC 9341 as the test organism [14]. The antibiotic concentration in both parts 
(total plasma and protein-free ultrafiltrate) was calculated using standard curves 
derived from solutions prepared with different antibiotic concentrations 
dissolved, respectively, in pooled mouse plasma and 0.9% NaCl. Analyses 
were performed in duplicate and the intraday and interday variation was <10%. 
 
PK analysis of novobiocin in total plasma and plasma ultrafiltrate was performed 
using TopFit V2 software (Karl Thomae, Boehringer–Ingelheim, Ingelheim, 
Germany) and a non-compartmental model. The area under the concentration–
time curve (AUC) of novobiocin from 0 min (time of administration) to 720 min 
was calculated using the linear trapezoidal rule. 
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Four non-infected animals were injected subcutaneously with four doses of 200 
mg/kg novobiocin at 1, 5, 24 and 48 h to monitor tolerance. Weight, aspect and 
behaviour of mice were examined daily for 1 week and weekly thereafter for 4 
weeks. In addition, the aspect (once a week) and survival of mice were 
observed for 4 months. 
 
2.6. Data analysis 
Survival rates were compared by Fisher’s exact test. Bacterial counts in 
peritoneal lavage of the different groups were presented as mean  S.D. and 
95% confidence interval. Comparison of peritoneal bacterial counts between 
two groups was performed by Mann–Whitney test, and comparisons among 
three or more groups were examined with Kruskal–Wallis test followed by 
Dunn’s multiple-comparisons test among groups when they were significantly 
different. Culture-negative samples (<10 CFU/mL) were included in the 
calculation of means assuming a value at the detection limit (1.0 log10 CFU/mL). 
A P-value of <0.05 was considered significant. 
 
3. Results 
3.1. Minimum inhibitory concentrations and time–kill curves 
Novobiocin and amoxicillin MICs, respectively, of the study organisms were as 
follows: strain AR33118, 0.25 mg/L and 0.015 mg/L; strain MJD3693, 0.5 mg/L 
and 8 mg/L; strain SPC2162, 0.25 mg/L and 16 mg/L; and strain SPC2552, 0.5 
mg/L and 64 mg/L. 
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Time–kill data for the four S. pneumoniae strains are presented in Table 1. 
Baseline inocula ranged from 6.03 log10 CFU/mL to 6.75 log10 CFU/mL (time 
zero). Novobiocin exposure resulted in a >2 log10 difference in viable counts 
versus the controls for all strains and all concentrations tested by 5 h, except for 
strains AR33118 and SPC2162 at 2 MIC. The antibacterial effect of amoxicillin 
was more potent and rapid than that of novobiocin, achieving at 2 MIC a >2 
log10 difference by 2 h and >4 log10 difference by 5 h, but this effect was 
somewhat lower for the most resistant strain (SPC2552). As shown in Table 1, 
for novobiocin there was an increase in killing by increasing concentrations on 
MIC basis as well as on time basis by comparing 2 h vs. 5 h. 
 
3.2. Therapeutic efficacy in sepsis caused by amoxicillin-susceptible and -
resistant strains 
The in vivo efficacy of novobiocin against amoxicillin-susceptible and -resistant 
S. pneumoniae strains in a mouse sepsis model is shown in Fig. 1. With the 
treatment schedule consisting of four s.c. doses at 1, 5, 24 and 48 h after 
infection, both novobiocin 200 mg/kg and amoxicillin 25 mg/kg were associated 
with a 100% survival rate of mice infected with the amoxicillin-susceptible strain 
AR33118 (P < 0.01 vs. untreated control group). For this strain, novobiocin 100 
mg/kg achieved a 71% survival rate. 
 
With the amoxicillin-resistant strains, novobiocin 200 mg/kg achieved the 
highest protection (90–100% survivors), followed by amoxicillin 200 mg/kg (60–
100%), and these differences were statistically significant (P < 0.01) compared 
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with the controls, except for the group infected with strain SPC2162 and treated 
with amoxicillin 200 mg/kg, which had a 60% survival rate. Novobiocin 100 
mg/kg protected 50–87.5% of the animals, whereas amoxicillin 50 mg/kg 
protected only 14.3–25% of the animals, with the lowest survival rate in animals 
infected with the most resistant strain (SPC2552). Notably, against this strain 
the 200 mg/kg amoxicillin regimen gave protection (87.5% survivors) similar to 
that showed by novobiocin 100 mg/kg. 
 
Table 2 shows the peritoneal bacterial counts after therapy with novobiocin and 
amoxicillin regimens in mice with sepsis induced by four pneumococcal strains 
that were survivors and were humanely sacrificed for sampling at 72 h after 
infection or animals that died before 72 h. All control animals that died had >8 
log10 CFU/mL in the peritoneum (mean value 8.7 log10 CFU/mL, range 8.2–9.1 
log10 CFU/mL). 
 
All mice infected with the amoxicillin-susceptible strain (AR33118) and treated 
with both novobiocin 200 mg/kg and amoxicillin 25 mg/kg survived, and the 
bacterial load in the peritoneum was undetectable, whereas the mean decline in 
peritoneal bacterial counts of survivor mice treated with novobiocin 100 mg/kg 
compared with those of the control group was only 1.7 log units. 
 
Bacterial clearance (undetectable CFU/mL) in peritoneal lavage fluid after 
sacrifice of survivor mice infected with the amoxicillin-resistant strains was 
detected as follows: (a) among mice infected with strain MJD3693, in five of 
nine animals treated with the high-dose novobiocin regimen, in two of five mice 
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treated with the low-dose novobiocin regimen, and in seven of eight mice 
treated with the high-dose amoxicillin regimen; (b) among mice infected with 
strain SPC2162, in six of nine mice treated with novobiocin 200 mg/kg, in two of 
four mice treated with novobiocin 100 mg/kg, and in three of six mice treated 
with amoxicillin 200 mg/kg; and (c) among mice infected with strain SPC2552, 
in seven of eight mice receiving novobiocin 200 mg/kg, in two of seven mice 
receiving novobiocin 100 mg/kg, and in all seven mice receiving amoxicillin 200 
mg/kg. Overall, the killing effect of the different antibiotic regimens in the 
peritoneum in mice infected with the amoxicillin-resistant strains could be 
ranked as follows (mean log10 CFU/mL between treated and untreated control 
mice after 72 h): novobiocin 200 mg/kg (6.6) > amoxicillin 200 mg/kg (5.6) > 
novobiocin 100 mg/kg (3.7) > amoxicillin 50 mg/kg (0.7). 
 
3.3. Novobiocin pharmacokinetics and tolerance 
Single-dose PK studies performed in non-infected mice that received single s.c. 
doses of 200 mg/kg novobiocin demonstrated the following PK values for total 
plasma and ultrafiltrate, respectively: elimination half-life, 151 min and 215 min; 
AUC 945.0 mg h/L and 136.6 mg h/L; and maximal concentration 147 mg/L and 
18 mg/L. The level of protein binding in mouse plasma was 85%. 
 
Long-term evaluation revealed appropriate tolerance to novobiocin at the tested 
regimen, as assessed by observing the weight, aspect and behaviour of the 
treated mice for 4 weeks, as well as the aspect and survival for 4 months. 
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4. Discussion 
Multidrug-resistant and highly antibiotic-resistant pneumococci have emerged 
as significant pathogens causing community-acquired infections worldwide [15]. 
However, following the 2008 CLSI parenteral penicillin breakpoints for non-
meningitis pneumococcal isolates (intermediate, 4 mg/L; resistant, 8 mg/L) 
[13], there are few up-to-date published studies dealing with highly -lactam-
resistant pneumococci (penicillin MIC ≥ 8 mg/L), especially regarding their 
optimal antibiotic therapy [16–18]. Among therapeutic strategies for combating 
pneumococcal infections caused by highly -lactam-resistant strains, here we 
have explored the use of novobiocin, an old drug, which we hypothesise could 
be re-introduced to the antibiotic armamentarium specifically for therapy of 
pneumococcal infections caused by strains with high-level resistance to the 
clinically used antibiotics. 
 
Novobiocin was extensively used before the development of broad-spectrum 
agents such as -lactam and quinolone agents. Because novobiocin displays 
potent activity against staphylococci, including meticillin-resistant 
Staphylococcus aureus (MRSA), pneumococci, enterococci and many other 
Gram-positive organisms [5,6], during the 1980s the suitability of clinical re-
evaluation of this drug was suggested [6]. Clinical trials conducted in the 1990s 
demonstrated the efficacy of novobiocin-containing combinations for eradicating 
the carrier state of MRSA [19,20]. Indeed, novobiocin combined with rifampicin 
prevented the development of resistance in MRSA to either drug even more 
efficiently than the combination of co-trimoxazole and rifampicin [20]. 
Remarkably, among severely ill patients with haematological disorders, the 
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combination of novobiocin with doxycycline or rifampicin was effective for the 
treatment of vancomycin-resistant Enterococcus faecium bacteraemia [21]. 
Regarding the side effects associated with the use of novobiocin alone or in 
combination, it should be stressed that many patients [19,20,22] and healthy 
volunteers [23,24] received this drug, mostly at 500 mg every 12 h for a variable 
period of time, without reporting relevant toxicity, and it has been suggested that 
some of the side effects could be attributed to impurities in the formulation that 
have since been removed [20]. Besides, novobiocin has also been administered 
as a modulator of alkylating agent cytotoxicity combined with 
cyclophosphamide, with the maximum tolerated dose being 6 g/day of 
novobiocin [25]. 
 
The in vitro results using time–kill curves show that the antibacterial effect of 
amoxicillin is more potent and rapid than that of novobiocin but the 
concentrations of amoxicillin used (16–512 mg/L) for the amoxicillin-resistant 
strains were much higher than those of novobiocin (0.5–16 mg/L). 
 
In the mouse sepsis model induced by an amoxicillin-susceptible pneumococcal 
strain, the highest dosage of novobiocin (200 mg/kg) was as effective as 
amoxicillin 25 mg/kg in terms of survival and killing of the peritoneal bacterial 
load. Results with the amoxicillin-resistant strains show that dosages of 200 
mg/kg novobiocin or amoxicillin were needed to cure most animals. 
Nevertheless, survival in animals inoculated with strain SPC2162 was, 
respectively, 100% and 60% when treated with 200 mg/kg of both novobiocin 
and amoxicillin. 
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The doses selected for amoxicillin administration were based on the results 
from a previous study by our group [26] which showed that the maximum 
amoxicillin concentrations attained in mouse serum after single doses of 
amoxicillin of 200 mg/kg and 50 mg/kg were 300 mg/L and 75 mg/L, 
respectively. However, such high amoxicillin concentrations cannot be achieved 
in patients following oral administration of usual dosages. In fact, peak levels of 
amoxicillin of 7.5 mg/L and 4 mg/L in the blood of patients occur 2 h after 
ingestion of 500 mg and 250 mg doses taken fasting, respectively [27,28], so 
only a high dose of this drug administered parenterally could achieve a peak 
serum concentration closed to 100 mg/L. On the other hand, a PK study carried 
out in humans, as determined by HPLC, showed that after ingestion of 
novobiocin at 500 mg every 12 h the mean peak serum concentration was 62.5 
 13.4 mg/L with an AUC of 407 mg h/L and a half-life of ca. 6 h [23], but even 
higher concentrations can be achieved following parenteral administration. For 
a highly protein-bound drug such as novobiocin, free drug concentrations must 
be determined, and our results show that maximum survival of animals was 
achieved with a free peak plasma concentration of ca. 18 mg/L. Our results also 
show that novobiocin could achieve sufficient concentrations to eradicate highly 
-lactam-resistant pneumococcal strains, whereas amoxicillin does not. 
 
Lastly, to our knowledge there is insufficient experimental evidence on the 
development of novobiocin resistance in pneumococci to preclude its use for 
the therapy of multidrug-resistant pneumococcal infections. Very few studies 
have approached this problem in S. pneumoniae. An in vitro study by Muñoz et 
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al. [29] described that a specific amino acid change (Ser-127Leu) in the DNA 
gyrase B subunit of S. pneumoniae increases novobiocin resistance, with MICs 
of 1 mg/L to 128 mg/L for the novobiocin-susceptible and -resistant strain, 
respectively. 
 
In conclusion, until novel antibacterial agents are discovered, our in vitro and in 
vivo data suggest that novobiocin may be a therapeutic alternative in 
pneumococcal infections caused by highly -lactam-resistant strains. 
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Fig. 1. Survival of mice with sepsis infected with four different Streptococcus 
pneumoniae strains: , non-treated controls; , novobiocin 25 mg/kg; ■, 
novobiocin 50 mg/kg; , novobiocin 100 mg/kg; ▲, novobiocin 200 mg/kg; +, 
amoxicillin 25 mg/kg; ○, amoxicillin 50 mg/kg; , amoxicillin 200 mg/kg. 
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Table 1 
Time–kill experiments of four Streptococcus pneumoniae strains after exposure to novobiocin or amoxicillin at 2, 8 and 32 times the 
minimum inhibitory concentration (MIC) 
Strain (MIC a) Time (h) Differences in log10 CFU/mL 
b 
Novobiocin Amoxicillin 
2 MIC 8 MIC 32 MIC 2 MIC 8 MIC 32 MIC 
AR33118 (0.25, 0.015) 2 0.68 ± 0.21 1.36 ± 0.16 1.45 ± 0.04 3.96 ± 0.12 4.18 ± 0.20 3.88 ± 0.11 
5 1.29 ± 0.05 2.71 ± 0.51 3.04 ± 0.15 4.33 ± 1.42 4.36 ± 0.32 5.80 ± 1.01 
MJD3693 (0.5, 8) 2 1.31 ± 0.06 1.58 ± 0.16 1.72 ± 0.08 2.58 ± 0.16 3.16 ± 0.03 3.18 ± 0.01 
5 2.89 ± 0.05 3.35 ± 0.1 3.50 ± 0.01 4.73 ± 0.09 4.68 ± 0.14 4.68 ± 0.35 
SPC2162 (0.25, 16) 2 1.20 ± 0.16 1.53 ± 0.14 1.75 ± 0.10 2.46 ± 0.00 2.68 ± 0.09 2.17 ± 0.15  
5 1.96 ± 0.01 3.13 ± 0.10 3.74 ± 0.25 4.64 ± 0.33 4.66 ± 0.04 3.62 ± 0.03 
SPC2552 (0.5, 64) 2 1.55 ± 0.14 1.90 ± 0.5 2.36 ± 0.23 2.55 ± 0.28 1.85 ± 0.02 NT 
5 2.98 ± 0.33 3.59 ± 0.03 4.17 ± 0.12 4.10 ± 0.67 3.64 ± 0.21 NT 
CFU, colony-forming units; NT, not tested. 
a Novobiocin and amoxicillin MICs (mg/L), respectively. 
b Differences in bacterial colony counts between those found in antibiotic-containing tubes and those shown in control tubes at 2 h 
and 5 h (inocula ranged from 6.03 log10 CFU/mL to 6.75 log10 CFU/mL at time zero). 
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Table 2 
Bacterial counts (mean  standard deviation) in peritoneal fluid and survival after therapy with novobiocin and amoxicillin regimens 
in mice with sepsis induced by four Streptococcus pneumoniae strains a 
Drug regimen b Log10 CFU/mL in survivor/log10 CFU/mL in dead animals (no. of survivor/no. of dead mice) 
c 
Strain AR33118 Strain MJD3693 Strain SPC2162 Strain SPC2552 
Control None d/9.1  0.4 (0/6) 3.3/9.1  0.7 (1/9) 3.4  1.7/8.2  0.8 (2/8) None d/8.3  0.6 (0/8) 
Novobiocin 
25 mg/kg None d/8.9  1.1 (0/3) NT NT NT 
50 mg/kg None d/8.2  1.1 (0/6) NT NT NT 
100 mg/kg 7.4  1.5/8.5  0.7 (5/2) 5.6  4.3/7.2  0.2 (5/3) 3.5  2.4/6.7  2.8 (4/4) 2.9  1.5 */5.7 (7/1) 
200 mg/kg <1.0 */None d (5/0) 2.0  1.3 */6.2 (9/1) 1.8  1.7 */None d (9/0) 1.5  1.4 */None d (8/0) 
Amoxicillin 
25 mg/kg <1.0 */None d (4/0) NT NT NT 
50 mg/kg NT 5.7  3.5/9.2  0.8 (2/6) 5.2  4.8/8.0  0.5 (2/6) <1.0/8.9  0.0 (1/6) 
200 mg/kg NT 1.4  1.2 */None d (8/0) 3.7  3.1/8.2  0.8 (6/4) <1.0 */7.3 (7/1) 
NT, not tested. 
a The respective novobiocin/amoxicillin MICs of strains AR33118, MJD3693, SPC2162 and SPC2552 were 0.25/0.015, 0.5/8, 
0.25/16 and 0.5/64 mg/L. 
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b Doses were given at 1, 5, 24 and 48 h after infection. 
c Evaluation was performed at 72 h after the start of therapy or before if the animal was found dead. 
d No bacterial counts are shown because there were no animals in these groups. 
* P < 0.05 versus controls. 
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FIG. 1. 
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